XOMA (NASDAQ:XOMA – Free Report) had its price target increased by HC Wainwright from $74.00 to $117.00 in a research note released on Thursday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for XOMA’s Q3 2024 earnings at ($0.32) EPS, Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($0.96) EPS, FY2025 earnings at $0.15 EPS and FY2026 earnings at $0.60 EPS.
A number of other research firms have also recently weighed in on XOMA. Leerink Partnrs restated an outperform rating on shares of XOMA in a research note on Monday, April 29th. SVB Leerink began coverage on XOMA in a research report on Monday, April 29th. They set an outperform rating and a $40.00 target price on the stock. Finally, StockNews.com raised XOMA from a sell rating to a hold rating in a report on Wednesday, August 14th.
Read Our Latest Analysis on XOMA
XOMA Price Performance
Institutional Trading of XOMA
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD purchased a new position in XOMA during the first quarter worth about $212,000. Bank of New York Mellon Corp boosted its position in shares of XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after purchasing an additional 1,968 shares in the last quarter. Rhumbline Advisers grew its stake in shares of XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after purchasing an additional 1,334 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in XOMA by 55.6% in the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 1,266 shares in the last quarter. 95.92% of the stock is owned by hedge funds and other institutional investors.
About XOMA
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
Further Reading
- Five stocks we like better than XOMA
- Most active stocks: Dollar volume vs share volume
- This Small Cap Wealth Management Stock Could Provide Big Returns
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What Makes a Stock a Good Dividend Stock?
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.